Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Physiomics ( (GB:PYC) ) has issued an announcement.
Physiomics plc announced a joint publication with Astellas Pharma Inc. in the journal ‘CPT: Pharmacometrics & Systems Pharmacology,’ detailing a study on optimizing treatment regimens for an oncolytic virus combined with Pembrolizumab. The study highlights the importance of dose and scheduling optimization in immunotherapy, a promising cancer treatment approach. The use of Physiomics’ Virtual Tumour platform demonstrates their capability to assist in developing innovative therapies by accelerating and de-risking the drug development process, reinforcing their position as a valuable partner for pharmaceutical companies in developing advanced cancer treatments.
More about Physiomics
Physiomics plc is a leading company in mathematical modelling, data science, and biostatistics, supporting the development of new therapeutics and personalized medicine solutions. The company helps biotech and pharma companies streamline their drug development processes through its expertise in modelling and simulation, biostatistics, and bioinformatics, offering services that optimize research design and decision-making across discovery, pre-clinical, and clinical studies.
YTD Price Performance: 10.0%
Average Trading Volume: 2,224,633
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.68M
Learn more about PYC stock on TipRanks’ Stock Analysis page.
